CCI approves merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for the acquisition of approximately 15% equity shareholding of Biocon Biologics by Serum Institute Life Sciences
By PIB Delhi
The Competition Commission of India (CCI) approves the merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for the acquisition of approximately 15% equity shareholding of Biocon Biologics by Serum Institute Life Sciences
The Proposed Combination involves a merger by absorption of Covidshield Technologies Private Limited (CTPL), a wholly-owned subsidiary of the Serum Institute Life Sciences Private Limited (Acquirer) into the Biocon Biologics Limited (Target) pursuant to a scheme of the merger in consideration of which the Acquirer will acquire approximately 15% equity shareholding on a fully diluted basis in the Target.
The Acquirer is a subsidiary of Serum Institute of India Private Limited and was established as a company for the further development and commercialization of vaccines and therapies against COVID-19. It also had plans to further develop vaccines against other infectious diseases. At present, the Acquirer is in the process of setting up its own manufacturing facility.
CTPL is a wholly-owned subsidiary of the Acquirer, which shall be merged into the Target pursuant to the Proposed Transaction. It was incorporated to undertake the business of marketing, selling, and distributing vaccines, drugs, and other pharmaceutical products.
The Target is a subsidiary of Biocon Limited, and it offers treatment for chronic and acute diseases such as diabetes, oncology, nephrology, cancer, and autoimmune diseases. Target also has research and development centres in Bengaluru and Chennai. It has manufacturing facilities in Bengaluru and Malaysia for monoclonal antibodies, recombinant proteins, and insulins.
Detailed order of the CCI will follow.
